9. Post-injected reactions and efficacy of the Covid-19 Comirnaty vaccine in children 12 - 17 years old at E-Hospital

Trương Van Quy, Nguyen Thi Dieu Thuy, Dao Thuy Quynh, Ninh Thi Phuong Mai

Main Article Content

Abstract

This is a cross-sectional descriptive study to describe post-injection reactions and assessment of effectiveness after 3 months of COVID-19 COMIRNATY vaccination in children at the age of 12 - 17 years old at E-Hospital. The cross-sectional descriptive study was carried out on 282 children from 12 to 17 years old , who were vaccinated against COVID-19 COMIRNATY at E-Hospital from October 2021 to April 2022. The rate of post-injected reactions after the 1st and 2nd injection was 77% and 65.6% respectively; the most common reactions were swelling and pain at the injected site, body aches, headache, accounting for 60.3%; 61% and 29.1% respectively after the 1st dose and 50.2%; 46.5% and 27.2% respectively after the 2nd dose. 100% of children who received two full doses of the vaccination did not need hospitalization and recovered to normal after contracting COVID-19. Most of the post-injected reactions with COVID-19 COMIRNATY vaccine were mild, and occurred within the first 3 days after injection. The rate of hospitalization, occurrence of severe symptoms, and mortality were markedly low in the group of children who received 2 doses of COVID-19 COMIRNATY vaccine when they contracted COVID-19 within 3 months of vaccination.

Article Details

References

1. Coronavirus Resource Center of Johns Hopkins University and Medicine (JHU). COVID-19 dashboard. https://coronavirus.jhu.edu/map.html. Published April 25, 2022. Accessed April 25, 2022.
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/measures. Published April 25, 2022. Accessed April 25, 2022.
3. Zheng C, Shao W, Chen X, et al. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. International Journal of Infectious Diseases. 2022; 114:252-260. doi: 10.1016/j.ijid.2021.11.009.
4. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 Months. N Engl J Med. 2021; 385(19): 1761-1773. doi: 10.1056/NEJMoa2110345.
5. Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in Adolescents. N Engl J Med. 2021; 385(3): 239-250. doi:10.1056/NEJMoa2107456.
6. Nguyễn Thị Hà, Ngô Văn Lăng, Đặng Hùng Dũng, Đặng Hùng Mạnh. Chấp nhận của cha/mẹ cho trẻ từ 5 - 11 tuổi tiêm vắc xin phòng COVID-19 tại các quận nội thành thành phố Hà Nội và một số yếu tố liên quan năm 2022. Tạp chí Y học Việt Nam. 2022; 512(2)71-77.
7. Nguyễn Hồng Minh, Nguyễn Thị Hà, Đặng Hùng Mạnh. Một số yếu tố liên quan tới chấp nhận của cha/mẹ cho trẻ từ 5 - 11 tuổi tiêm vắc xin phòng COVID-19 tại Phúc Thọ - Hà Nội. Tạp chí Y học Việt Nam. 2022; 512(2): 209-214.
8. Quyết định số 3588/QĐ-BYT về việc Ban hành hướng dẫn tổ chức buổi tiêm chủng vắc xin phòng COVID-19 (2021).
9. Hướng dẫn chẩn đoán và điều trị COVID-19 của Bộ Y tế theo quyết định số 250/QĐ-BYT (2022).
10. Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(31): 1053-1058. doi: 10.15585/mmwr.mm7031e1.
11. Nikolopoulou GB, Maltezou HC. COVID-19 in Children: Where do we Stand? Arch Med Res. 2022; 53(1): 1-8. doi: 10.1016/j.arcmed.2021.07.002.
12. Szczepanek J, Skorupa M, Goroncy A, et al. Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines. Vaccines (Basel). 2022; 10(1). doi: 10.3390/vaccines10010099.
13. Nguyễn Anh Trí, Nguyễn Thị Kim Len, Trịnh Thị Quế, và cs. Nghiên cứu thực trạng miễn dịch cộng đồng với SARS-CoV-2 tại thành phố Hà Nội. Tạp chí Y học Việt Nam. 2022; 511(2): 44-48. doi: 10.51298/vmj.v511i2.2109.
14. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020; 4(9): 653-661. doi: 10.1016/s2352-4642(20)30177-2.
15. Parri N, Magistà AM, Marchetti F, et al. Characteristic of COVID-19 infection in pediatric patients: Early findings from two Italian Pediatric Research Networks. Eur J Pediatr. 2020; 179(8): 1315-1323. doi: 10.1007/s00431-020-03683-8.